Physician profile
Krishna Uppu
NPI 1265567325
$4,948.61
in general payments reported to CMS, 2019-2025
19 companies · $2,518 in 2025
The $2,518 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2021: $46.73 · 2023: $171 · 2024: $1,858 · 2025: $2,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,500 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,500.23 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $979.87 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $794.61 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $759.95 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $454.32 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $392.10 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $351.95 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $275.31 | 2019-2025 | Lybalvi, Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $250.36 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $207.86 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $176.90 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $76.06 | 2024-2025 | Aplenzin, Wellbutrin |
| Corcept Therapeutics | $68.87 | 2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $38.30 | 2025 | Qelbree |
| Luye Pharma (USA) LTD. | $26.95 | 2025 | Erzofri Extended-Release |
| Teva Pharmaceuticals USA, INC. | $21.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.79 | 2025 | Wegovy |
| Astellas Pharma US INC | $20.32 | 2025 | Veozah |
| Exact Sciences Corporation | $18.58 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $14.18 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Uppu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.